Photodynamic Therapy / mitResp Cancer Research Results

PDT, Photodynamic Therapy: Click to Expand ⟱

Features: Therapy

Photodynamic therapy is a form of phototherapy involving light and a photosensitizing chemical substance used in conjunction with molecular oxygen to elicit cell death.
Photodynamic therapy (PDT) is a 3-component cytotoxic platform: photosensitizer + light (matched wavelength) + oxygen. Light excites the photosensitizer, which then generates reactive oxygen species (ROS)—often dominated by singlet oxygen (¹O₂)—causing localized oxidative damage to tumor cells, tumor vasculature, and sometimes triggering immunogenic cell death (ICD).
Key constraints are light penetration depth and tumor hypoxia (and PDT itself can transiently consume oxygen).

Photodynamic Therapy (PDT) — Cancer-Oriented Time-Scale Flagged Pathway Table

Rank	Pathway / Axis	Cancer / Tumor Context	Normal Tissue Context	TSF	Primary Effect	Notes / Interpretation
1	Type II photochemistry: singlet oxygen (¹O₂) generation	¹O₂ ↑↑ locally; oxidative damage ↑	Localized injury only where PS+light overlap	P	Core cytotoxic mechanism	PDT typically relies heavily on Type II energy transfer producing singlet oxygen as a primary cytotoxic agent (oxygen-dependent).
2	Type I photochemistry: radical ROS (O2•−, •OH, etc.)	Radical ROS ↑ (context; PS-dependent)	Localized oxidative injury (exposure-limited)	P	ROS amplification	Type I electron-transfer pathways can contribute, especially for some PS designs and oxygen-limited niches.
3	Direct tumor cell kill (membrane/protein/DNA oxidation)	Apoptosis/necrosis/other death programs ↑ (context)	Collateral damage limited by targeting + light field	R, G	Local tumor cytotoxicity	Oxidative injury can trigger multiple death modes; outcome depends on dose, PS localization (membrane/mitochondria/lysosome), and oxygen.
4	Vascular shutdown (tumor vasculature damage)	Perfusion ↓; secondary hypoxia/ischemia ↑	Local vascular injury possible	R	Indirect tumor starvation	PDT can damage tumor-associated vessels, restricting nutrient/oxygen supply and contributing to delayed tumor kill.
5	Oxygen dependence / hypoxia limitation	Efficacy ↓ in hypoxic tumors; PDT consumes O2 during reaction	—	P, R	Core constraint	Tumor hypoxia is a major barrier; PDT can transiently reduce local oxygen levels during illumination.
6	Immune activation / immunogenic cell death (ICD)	DAMP release ↑; anti-tumor immunity ↑ (protocol/PS-dependent)	Inflammatory signaling ↑ locally	G	Systemic immune leverage	PDT can trigger ICD and stimulate adaptive immune responses, but this is highly dependent on photosensitizer and protocol.
7	Inflammation & cytokine wave (acute)	Local cytokines ↑; immune cell recruitment ↑	Local inflammation ↑	R, G	Microenvironment remodeling	Post-PDT inflammation can support tumor clearance or, if suboptimal, contribute to repair/regrowth; protocol matters.
8	Combination leverage (radiation/chemo/immunotherapy)	Sensitization ↑ (context-dependent)	—	G	Adjunct synergy	PDT is often paired with other modalities; strongest logic is local tumor kill + immune priming + improved control of residual disease.
9	Light penetration depth constraint	Deep tumors harder to treat (limited light reach)	—	—	Translation constraint	Most activation light has limited tissue penetration; strategies include fiber optics, endoscopic delivery, or NIR-shifted PS designs.
10	Photosensitizer PK & phototoxicity risk	PS accumulation affects selectivity	Skin/eye photosensitivity risk (agent-dependent)	R, G	Clinical constraint	Systemic photosensitizers can cause prolonged photosensitivity; topical/ALA-based approaches reduce systemic exposure in some uses.

Time-Scale Flag (TSF): P / R / G

P: 0–30 min (photoactivation + ROS burst)
R: 30 min–3 hr (vascular effects, acute stress signaling)
G: >3 hr (cell-death completion, immune recruitment, ICD outcomes)

Common Clinical Photosensitizers for Cancer PDT

Photosensitizer	Class	Activation Wavelength (nm)	Penetration Depth*	Photosensitivity Duration	Typical Clinical Use	Notes
5-ALA (→ Protoporphyrin IX)	Endogenous porphyrin precursor	~630–635 nm	Shallow–Moderate (~2–5 mm)	Short (24–48 hrs; topical shorter)	Skin cancers, actinic keratosis, bladder, glioma visualization	Prodrug converted intracellularly to PpIX; good tumor selectivity; minimal prolonged systemic photosensitivity.
Porfimer sodium (Photofrin®)	First-generation porphyrin	~630 nm	Moderate (~5–10 mm)	Long (4–6 weeks)	Esophageal, lung, bladder cancers	Prolonged skin photosensitivity is a major limitation.
Temoporfin (Foscan®)	Chlorin	~652 nm	Moderate (~5–10 mm)	2–3 weeks	Head & neck cancers	Higher potency than Photofrin; improved absorption spectrum.
Verteporfin (Visudyne®)	Benzoporphyrin derivative	~689 nm	Moderate–Deeper (~5–10+ mm)	Short (few days)	Primarily ophthalmology; investigated in oncology	Better red/NIR absorption; shorter photosensitivity window.
Talcaporfin sodium (Laserphyrin®)	Chlorin derivative	~664 nm	Moderate (~5–10 mm)	Short (~1–2 weeks)	Lung, brain tumors (Japan)	Improved safety vs first-generation porphyrins.
Methylene Blue	Phenothiazine dye	~660–670 nm	Shallow–Moderate	Short	Experimental oncology; antimicrobial PDT	Strong Type I ROS contribution; also has redox cycling effects without light.
Hypericin	Natural anthraquinone	~590–600 nm	Shallow	Variable	Investigational	High singlet oxygen yield; hydrophobic; not widely used clinically.

*Penetration depth depends on wavelength, tissue optical properties, and light delivery method. Red/NIR light (~650–700 nm) penetrates deeper than blue/green light.

mitResp, mitochondrial respiration: Click to Expand ⟱

Source:

Type:

Mitochondrial respiration plays a crucial role in the development and progression of cancer. Cancer cells often exhibit altered metabolic profiles, including changes in mitochondrial respiration, to support their rapid growth and proliferation.

In cancer cells, mitochondrial respiration is often downregulated, and instead, they rely on glycolysis for energy production, even in the presence of oxygen. This phenomenon is known as the "Warburg effect."

There are several key players involved in the regulation of mitochondrial respiration in cancer cells, including:

Pyruvate dehydrogenase (PDH): a critical enzyme that converts pyruvate into acetyl-CoA, which is then fed into the citric acid cycle.
Citrate synthase: an enzyme that catalyzes the first step of the citric acid cycle.
Succinate dehydrogenase (SDH): an enzyme that participates in both the citric acid cycle and the electron transport chain.
Cytochrome c oxidase (COX): the final enzyme in the electron transport chain, responsible for generating ATP.
Alterations in the expression and activity of these enzymes can impact mitochondrial respiration in cancer cells. For example, increased expression of PDH and citrate synthase can enhance mitochondrial respiration, while decreased expression of SDH and COX can impair it.

Additionally, various transcription factors and signaling pathways regulate mitochondrial respiration in cancer cells, including:

HIF-1α (hypoxia-inducible factor 1 alpha): a transcription factor that promotes glycolysis and suppresses mitochondrial respiration in response to hypoxia.
c-Myc: a transcription factor that regulates the expression of genes involved in mitochondrial respiration and biogenesis.
PI3K/Akt/mTOR: a signaling pathway that promotes cell growth and proliferation, in part by regulating mitochondrial respiration.

Scientific Papers found: Click to Expand⟱

1175-

IVM,

PDT,

Drug induced mitochondria dysfunction to enhance photodynamic therapy of hypoxic tumors

in-vitro,

Var,

Hypoxia↓, mitResp↓, ROS↑,

Showing Research Papers: 1 to 1 of 1

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 1

Pathway results for Effect on Cancer / Diseased Cells:

Redox & Oxidative Stress ⓘ

ROS↑, 1,

Mitochondria & Bioenergetics ⓘ

mitResp↓, 1,

Angiogenesis & Vasculature ⓘ

Hypoxia↓, 1,
Total Targets: 3

Pathway results for Effect on Normal Cells:

Total Targets: 0

Scientific Paper Hit Count for: mitResp, mitochondrial respiration

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells